NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )
The new high flow capabilities for the System One will enable dialysate flow rates which allow nephrologists expanded possibilities to adjust the duration and frequency of patient prescriptions with greater flexibility than they have today.
Our new high flow capabilities advance the therapeutic flexibility of the System One as well as NxStage’s leadership in home therapies, said
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) provide convenient use in patients’ homes and give patients the freedom to travel with their therapy. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on the road.
About
NxStage is a medical device company, headquartered in
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the
CONTACT:
SOURCE
News Provided by Acquire Media
